AMLX Stock Recent News

Amylyx (AMLX) makes a formal decision to remove its amyotrophic lateral sclerosis drug from the U.S. and Canadian markets. The company is expected to reduce its workforce by 70%.

The decision to remove Relyvrio from the market comes after the drug failed a Phase 3 trial.

Amylyx Pharmaceuticals said on Thursday it would withdraw its amyotrophic lateral sclerosis (ALS) drug from the U.S. and Canada markets after the treatment failed in a crucial late-stage trial.

Following the study's failure, Amylyx (AMLX) is now uncertain whether to pull its orally administered ALS drug from the market. Management has voluntarily decided to pause all promotions of the drug.

Amylyx's ALS drug failed a late-stage trial, raising questions about the future of the drug and the company itself.

Relyvrio, which is sold under the name Albrioza in Canada, is Amylyx's only product.

Amylyx Pharmaceuticals said on Friday its drug to treat a neurological disorder called ALS, or amyotrophic lateral sclerosis, failed to meet the main goal in a late-stage confirmatory study.

Amylyx Pharmaceuticals, Inc. (AMLX) came out with quarterly earnings of $0.07 per share, missing the Zacks Consensus Estimate of $0.20 per share. This compares to loss of $0.65 per share a year ago.

I have always said it, and I keep my word regarding the biotechnology sector, since it is one of the largest and most important sectors. Not only is it vital for the financial markets, but for the quality of human life.

Investors with an interest in Medical - Drugs stocks have likely encountered both Amylyx Pharmaceuticals, Inc. (AMLX) and Neurocrine Biosciences (NBIX). But which of these two companies is the best option for those looking for undervalued stocks?